Bibliographic Citation
| - Beau-Faller Michèle, Texier Matthieu, Blons Hélène, Richard Nicolas, Escande Fabienne, Melaabi Samia, Lizard Sarab, De Fraipont Florence, Longchampt Elisabeth, Morin Franck, Zalcman Gérard, Pignon Jean-Pierre, Cadranel Jacques. Clinical Relevance of EGFR - or KRAS - mutated Subclones in Patients With Advanced Non–small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2). Clinical Lung Cancer, Elsevier, 2019, 20 (3), pp.222-230. ⟨10.1016/j.cllc.2018.12.012⟩
- Beau-Faller Michèle, Texier Matthieu, Blons Hélène, Richard Nicolas, Escande Fabienne, Melaabi Samia, Lizard Sarab, de Fraipont Florence, Longchampt Elisabeth, Morin Franck, Zalcman Gérard, Pignon Jean-Pierre, Cadranel Jacques . Clinical Relevance of EGFR - or KRAS - mutated Subclones in Patients With Advanced Non–small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2) . Clinical Lung Cancer, 2019, 20 (3), pp.222-230 . ⟨10.1016/j.cllc.2018.12.012⟩
- Beau-Faller Michèle, Texier Matthieu, Blons Hélène, Richard Nicolas, Escande Fabienne, Melaabi Samia, Lizard Sarab, de Fraipont Florence, Longchampt Elisabeth, Morin Franck, Zalcman Gérard, Pignon Jean-Pierre, Cadranel Jacques. Clinical Relevance of EGFR - or KRAS - mutated Subclones in Patients With Advanced Non–small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2). Clinical Lung Cancer, 2019, 20 (3), pp.222-230. ⟨10.1016/j.cllc.2018.12.012⟩
|